EMBARKING ON AN EXCITING JOURNEY

Transcription

1 EMBARKING ON AN EXCITING JOURNEY Søren Tulstrup CEO Vifor Pharma Media Conference, 10 March 2015 THE GALENICA GROUP EXCELLENCE IN THE HEALTHCARE MARKET

2 Clear & inspiring Vision Vifor Pharma will become a successful, stand-alone global specialty pharma company within two to four years. 2 Galenica Group

3 Excellent progress made in all Vifor Pharma projects Organisational changes to improve competitiveness, strengthen Vifor Pharma geographic and therapeutic focus and ensure that Vifor Pharma continues to be aligned. 2. Expansion of Vifor Pharma iron franchise. 3. Injectafer : steadily penetrated high-dose segment. 4. Ferinject : Marketing authorisation received in 12 further countries. 5. Velphoro : EU approval received, launched in Germany, Portugal and the USA. 6. Grew Vifor Pharma infectious disease and consumer brands. 7. Provided world-class manufacturing to pharmaceutical customers. 3 Galenica Group

4 Vifor Pharma Overall growth of +6.6% vs. prior year 2014 in MCHF ±% prior year Total Vifor Pharma % Core Business % Rx % Infectious diseases/otx % CHC International % CHC Switzerland % 3rd party manufacturing % 4 Galenica Group

5 Ferinject Sales growth driver of the iron franchise in MCHF ±% prior year ±% in volume ±% in IMS* Ferinject % +28.1% +42.0%* Venofer % +22.4% +0.2%** Maltofer % -4.9% +13.7%** 5 Galenica Group *MAT 12/2014; MAT for panels not available on MTH basis (3% of FJ sales); **MAT

6 Ferinject Solid volume growth in key countries ±% in volume ±% in IMS* Ferinject total +28.1% +30.4% Switzerland +5.6% +5.8% Germany +13.3% +14.2% France -25.9% -14.2% UK & Ireland +34.3% +36.0% Spain +29.4% +22.4% USA +1,390.7% +1,444.4% 100mg equivalents 6 Galenica Group *MAT 12/2014; MAT for panels not available on MTH basis (3% of FJ sales); Farma&Cia source for Spain, GERS for France

7 Injectafer steadily penetrated high-dose segment Injectafer building momentum in US market: J-code awarded in December 2014 and effective as of January Luitpold Pharmaceuticals initial focus in Hematology Infusion Clinic setting. Full program of promotional, reimbursement and medical education support. 20% volume share of high-dose segment. Customer and patient feedback has been very positive. Strong relationship and collaboration in place: Luitpold Pharmaceuticals benefiting from Vifor Pharma launch experience in EU countries. Close coordination across functions. Joint funding of key initiatives. Launch in Gastro (GI) planned April Galenica Group

8 Ferinject CONFIRM-HF study: Expanding the clinical evidence in Heart Failure (HF) Multicentre, randomised (1:1), double-blind, placebo-controlled trial Study results: Significant improvement in 6 minute walking distance (6MWT) at week 24 In symptomatic patients with chronic heart failure (CHF) and iron deficiency treatment with Ferinject over a one year period results in: Sustainable improvement in: Exercise capacity, symptoms, quality of life Is associated with a lower rate of hospitalization due to worsening heart failure 8 Galenica Group

9 Iron Deficiency is the most common nutrient deficiency in the world 1 Up to 4 to 5 billion people may suffer from iron deficiency. 2 Iron deficiency anaemia affects approximately 15% of the world population. 3 In the high developed countries 111 million people are affected. 4 9 Galenica Group ) World Health Organization (WHO) Micronutrient deficiencies: Iron deficiency anaemia. Available at Last accessed: 10 November ) Unicef Last accessed: 10 November ) Vos T Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries : a systematic analysis for the Global Burden of Disease Study 2010 Lancet Dec 15;380(9859): doi: /S (12) ) McLean E, Cogswell M, Egli I, Wojdyla D, de Benoist B. Worldwide prevalence of anaemia, WHO Vitamin and Mineral Nutrition Information System, Public Health Nutr. 2009;12(4): doi: /s

10 Increase disease awareness Educate people to recognise symptoms and seek help 10 Galenica Group

11 Venofer Remains the gold standard product in dialysis patients ±% prior year ±% in IMS* Venofer sales -11.9% +0.2% USA -8.6% +4.6% Others -14.9% +1.6% Gold standard position reinforced by data showing Venofer cannot be substituted by Iron Sucrose Similars (ISS). New branding helped to increase visibility of Venofer in the market and defend its position as market leader. Venofer has 85 marketing authorisations worldwide. 11 Galenica Group *MAT 12/2014 for US, MAT for total and ROW

12 Infectious diseases/otx Solid growth of all brands 2014 in MCHF ±% prior year ±% in IMS* Broncho-Vaxom % +1.5% Uro-Vaxom % +9.3% Doxium % +20.0% Dicynone % +6.1% 12 Galenica Group *MAT , in local currency Dollar

13 Fully exploit potential of Velphoro Pivotal phase III study demonstrated that Velphoro successfully controls hyperphosphatemia with fewer pills than sevelamer carbonate, the current standard of care in patients with CKD on dialysis 1. Currently the product is approved in 35 countries: 28 countries in the European Union, Norway, Iceland, Liechtenstein, Switzerland, USA, Australia and Singapore. Velphoro is launched in the USA, Germany, Portugal, UK and Denmark (status: March 2015). Further submissions are in preparation. Strong commercial partners with Fresenius Medical Care in USA and Europe, and Kissei Pharmaceutical Co., Ltd. in Japan. 13 Galenica Group Jürgen Floege et al. Efficacy and safety of a novel phosphate binder, Kidney International doi: /ki

14 Vifor Pharma key priorities Retain global leadership position in iron deficiency and ensure continued market expansion by executing a clear overall iron deficiency franchise strategy. 2. Ensure successful launch of Velphoro in the USA and the top five EU markets Germany, UK, Italy, France and Spain. 3. Continue growing the ID/OTX franchise in the key regions LATAM, Asia Pacific and Russia through an effective partner network while stabilizing the business in Europe. 14 Galenica Group

15 Vifor Pharma key priorities Secure ongoing profitable revenue stream from mature products by making highly targeted commercial investments and/or improving partner management. 5. Expand business base opportunistically: Make good deals to move into related markets/technologies. 6. Ensure optimal positioning to become an independent global specialty pharmaceutical company within the next 2 to 4 years. 15 Galenica Group

16 16 Galenica Group